Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta‐analysis

  • Guangqin Xiao
    Cancer Center, Union Hospital,Huazhong University of Science and Technology,Wuhan,China
  • Sixian Zhu
    Department of Oncology, Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China
  • Xiao Xiao
    Department of Nursing,Xinxiang Medical University,Xinxiang,China
  • Lunan Yan
    Department of Liver Surgery,West China Hospital of Sichuan University,Chengdu,China
  • Jiayin Yang
    Department of Liver Surgery,West China Hospital of Sichuan University,Chengdu,China
  • Gang Wu
    Cancer Center, Union Hospital,Huazhong University of Science and Technology,Wuhan,China

Search this article

Description

<jats:p>Many noninvasive methods for diagnosing liver fibrosis (LF) have been proposed. To determine the best method for diagnosing LF in nonalcoholic fatty liver disease (NAFLD), we conducted a systemic review and meta‐analysis to compare the performance of aspartate aminotransferase to platelets ratio index (APRI), fibrosis‐4 index (FIB‐4), BARD score, NAFLD fibrosis score (NFS), FibroScan, shear wave elastography (SWE), and magnetic resonance elastography (MRE) for diagnosing LF in NAFLD. We compared the sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve (AUROC) of these noninvasive methods for detecting significant fibrosis (SF), advanced fibrosis (AF), and cirrhosis. Heterogeneity was explored using meta‐regression. Sixty‐four articles with a total of 13,046 NAFLD subjects were included. The overall mean prevalence of SF, AF, and cirrhosis was 45.0%, 24.0%, and 9.4% in NAFLD patients, respectively. With an APRI threshold of 1.0 and 1.5, the sensitivities and specificities were 50.0% and 84.0% and 18.3% and 96.1%, respectively, for AF. With a FIB‐4 threshold of 2.67 and 3.25, the sensitivities and specificities were 26.6% and 96.5% and 31.8% and 96.0%, respectively, for AF. The summary sensitivities and specificities of BARD score (threshold of 2), NFS (threshold of −1.455), FibroScan M (threshold of 8.7‐9), SWE, and MRE for detecting AF were 0.76 and 0.61, 0.72 and 0.70, 0.87 and 0.79, 0.90 and 0.93, and 0.84 and 0.90, respectively. The summary AUROC values using APRI, FIB‐4, BARD score, NFS, FibroScan M probe, XL probe, SWE, and MRE for diagnosing AF were 0.77, 0.84, 0.76, 0.84, 0.88, 0.85, 0.95, and 0.96, respectively. <jats:italic toggle="yes">Conclusion:</jats:italic> MRE and SWE may have the highest diagnostic accuracy for staging fibrosis in NAFLD patients. Among the four noninvasive simple indexes, NFS and FIB‐4 probably offer the best diagnostic performance for detecting AF. (H<jats:sc>epatology</jats:sc> 2017;66:1486–1501).</jats:p>

Journal

  • Hepatology

    Hepatology 66 (5), 1486-1501, 2017-09-26

    Ovid Technologies (Wolters Kluwer Health)

Citations (20)*help

See more

Report a problem

Back to top